Clinical utility of 2′,5′-oligoadenylate synthetase activity measurement: Using whole blood as a highly sensitive method to detect the effects of IFN

Journal of Virological Methods

Volumn 136, Issue 1-2, 2006, Pages 185-192

  Uno, Kazuko ^a   Suginoshita, Yoshiki ^b   Kakimi, Kazuhiro ^b   Moriyasu, Yasunori ^b   Nakano, Koji ^c   Nakamura, Naoto ^c   Fujita, Toshio ^c   Horino, Yoshihiro ^d   Sato, Takayuki ^e   Kishida, Tsunataro ^a  

^a Louis Pasteur Center for Medical Research   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY   (Japan)

^d Faloco Biosystems   (Japan)

^e DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

2 ,5 Oligoadenyrate synthetase; Autoimmune diseases; IFN; Viral diseases; Weak IFN signal; Whole blood

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALPHA INTERFERON; CYTOKINE; HEPARIN; INTERFERON; RECOMBINANT ALPHA2 INTERFERON; RECOMBINANT ALPHA2A INTERFERON;

ARTICLE; AUTOIMMUNE DISEASE; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME ACTIVITY; HEPATITIS B; HEPATITIS C; HUMAN; INFECTION; MEASUREMENT; PRIORITY JOURNAL; RELIABILITY; SENSITIVITY ANALYSIS; THAWING;

2',5'-OLIGOADENYLATE SYNTHETASE; ADMINISTRATION, ORAL; BLOOD PRESERVATION; HEMOLYSIS; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERONS; PERIODICITY; SENSITIVITY AND SPECIFICITY; TEMPERATURE;

EID: 33745884374     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2006.05.005     Document Type: Article

References (36)

1. Billard C., Diez R.A., Ferbus D., Raynaud N., Dorval T., Pouillart P., Nielsen K., and Falcoff E. Similar biological effects of different low doses of interferon alpha in cancer patients. Br. J. Cancer 55 (1987) 677-679
2. Bonnevie-Nielsen V., Martensen P.M., Justesen J., Kyvik K.O., Kristensen B., Levin K., Beck-Nielsen H., Worsaa A., and Dyrberg T. The antiviral 2′,5′-oligoadenylate synthetase is persistently activated in type 1 diabetes. Clin. Immunol. 96 (2000) 11-18
3. Bosio E., Cluning C.L., and Beilharz M.W. Low-dose orally administered type I interferon reduces splenic B cell numbers in mice. J. Interferon Cytokine Res. 21 (2001) 721-728
4. Brand C.M., Leadbeater L., Bellati G., Marotta F., and Ideo G. Antibodies developing against a single recombinant interferon protein may neutralize many other interferon-alpha subtypes. J. Interferon Res. 13 (1993) 121-125
5. Buffet-Janvresse C., Magard H., Robert N., and Hovanessian A.G. Assay and the levels of 2-5A-synthetase in lymphocytes of patients with viral, bacterial and autoimmune diseases. Ann. Immunol. (Paris) 134D (1983) 247-258
6. Chousterman S., Chousterman M., Reinert P., and Thang M.N. Clinical value of the determination of an interferon-induced enzyme activity: studies of the 2′,5′-oligoadenylate synthetase activity in peripheral blood lymphocytes of patients. Biomed. Pharmacother. 37 (1983) 176-180
7. Corssmit E.P., Heijligenberg R., Hack C.E., Endert E., Sauerwein H.P., and Romijn J.A. Effects of interferon-alpha (IFN-alpha) administration on leucocytes in healthy humans. Clin. Exp. Immunol. 107 (1997) 359-363
8. Cummins J.M., Beilharz M.W., and Krakowka S. Oral use of interferon. J. Interferon Cytokine Res. 19 (1999) 853-857
9. Cummins J.M., Hutcheson D.P., Cummins M.J., Georgiades J.A., and Richards A.B. Oral therapy with human interferon alpha in calves experimentally injected with infectious bovine rhinotracheitis virus. Arch. Immunol. Ther. Exp. (Warsz) 41 (1993) 193-197
10. de Carli M., D'Elios M.M., Mariotti S., Marcocci C., Pinchera A., Ricci M., Romagnani S., and del Prete G. Cytolytic T cells with Th1-like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves' ophthalmopathy. J. Clin. Endocrinol. Metab. 77 (1993) 1120-1124
11. Heuer M., Aust G., Ode-Hakim S., and Scherbaum W.A. Different cytokine mRNA profiles in Graves' disease, Hashimoto's thyroiditis, and nonautoimmune thyroid disorders determined by quantitative reverse transcriptase polymerase chain reaction (RT-PCR). Thyroid 6 (1996) 97-106
12. Kakuta S., Shibata S., and Iwakura Y. Genomic structure of the mouse 2′,5′-oligoadenylate synthetase gene family. J. Interferon Cytokine Res. 22 (2002) 981-993
13. Karino Y., Sugawara T., Saga A., Yoshida J., Matsushima T., Miyazaki T., Toyota J., and Okuuchi Y. Serum 2′,5′-oligoadenylate synthetase as a monitoring marker of anti-viral effect during interferon therapy for chronic type B hepatitis. Gastroenterol. Jpn. 24 (1989) 164-169
14. Koech D.K., and Obel A.O. Efficacy of Kemron (low dose oral natural human interferon alpha) in the management of HIV-1 infection and acquired immune deficiency syndrome (AIDS). East Afr. Med. J. 67 (1990) SS64-SS70
15. Lecciones J.A., Abejar N.H., Dimaano E.E., Bartolome R., Cinco S., Mariano N., Yerro M.E., Cobar S., and Fuggan B. A pilot double-blind, randomized, and placebo-controlled study of orally administered IFN-alpha-n1 (Ins) in pediatric patients with measles. J. Interferon Cytokine Res. 18 (1998) 647-652
16. Levin S., and Hahn T. Interferon system in acute viral hepatitis. Lancet 1 (1982) 592-594
17. Nakajima A., and Sokawa Y. Induction of blood 2′,5′-oligoadenylate synthetase activity in mice by gastric administration of ovine IFN-tau. J. Interferon Cytokine Res. 22 (2002) 397-402
18. Okuno T., Shindo M., Arai K., Matsumoto M., Takeda M., Kashima K., and Sokawa Y. 2′,5′-Oligoadenylate synthetase activity in peripheral blood mononuclear cells and serum during interferon treatment of chronic non-A, non-B hepatitis. Gastroenterol. Jpn. 26 (1991) 603-610
19. Paschke R., Schuppert F., Taton M., and Velu T. Intrathyroidal cytokine gene expression profiles in autoimmune thyroiditis. J. Endocrinol. 141 (1994) 309-315
20. Pawlotsky J.M., Hovanessian A., Roudot-Thoraval F., Lebon P., Robert N., Bouvier M., Babany G., Duval J., and Dhumeaux D. Activity of the interferon-induced 2′,5′-oligoadenylate synthetase in patients with chronic hepatitis C. J. Interferon Cytokine Res. 15 (1995) 857-862
21. Pawlotsky J.M., Hovanessian A.G., Roudot-Thoraval F., Robert N., Bouvier M., Babany G., Duval J., and Dhumeaux D. Effect of alpha interferon (IFN-alpha) on 2′,5′-oligoadenylate synthetase activity in peripheral blood mononuclear cells of patients with chronic hepatitis C: relationship to the antiviral effect of IFN-alpha. Antimicrob. Agents Chemother. 40 (1996) 320-324
22. Russell I.J., Michalek J.E., Kang Y.K., and Richards A.B. Reduction of morning stiffness and improvement in physical function in fibromyalgia syndrome patients treated sublingually with low doses of human interferon-alpha. J. Interferon Cytokine Res. 19 (1999) 961-968
23. Russell I.J., Vipraio G.A., Michalek J.E., Craig F.E., Kang Y.K., and Richards A.B. Lymphocyte markers and natural killer cell activity in fibromyalgia syndrome: effects of low-dose, sublingual use of human interferon-alpha. J. Interferon Cytokine Res. 19 (1999) 969-978
24. Satoh Y., Kasama K., Kuwabara M., Yimin, Diao H.Y., Nakajima H., Kohanawa M., and Minagawa T. Suppression of late asthmatic response by low-dose oral administration of interferon-beta in the guinea pig model of asthma. J. Interferon Cytokine Res. 19 (1999) 887-894
25. Sawai H., Ishibashi K., Itoh M., and Watanabe S. Radioimmuno assay for 2-5 A using a novel 125I-labeled 2-5 A analog, and analysis of 2-5 A and 2-5OASynthetase activity in human plasma. Prog. Clin. Biol. Res. 202 (1985) 97-104
26. Sawai H., Ishibashi K., Itoh M., and Watanabe S. Sensitive radioimmuno assay for 2′,5′-oligoadenylates using a novel 125I-labeled derivative of 2′,5′-triadenylate 5′-triphosphate. J. Biochem. (Tokyo) 98 (1985) 999-1005
27. Schattner A., Wallach D., Merlin G., Hahn T., Levin S., and Revel M. Assay of an interferon-induced enzyme in white blood cells as a diagnostic aid in viral diseases. Lancet 2 (1981) 497-500
28. Shindo M., Okuno T., Matsumoto M., Takeda M., Takino T., Sokawa J., Iwata A., and Sokawa Y. Serum 2′,5′-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis B. Hepatology 8 (1988) 366-370
29. Shindo M., Okuno T., Arai K., Matsumoto M., Takeda M., Takino T., and Sokawa Y. Elevated levels of 2′,5′-oligoadenylate synthetase activity in peripheral blood mononuclear cells and serum during acute exacerbation of chronic hepatitis B. Hepatology 9 (1989) 715-719
30. Shiozawa S., Tanaka Y., and Shiozawa K. Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjogren's syndrome. J. Interferon Cytokine Res. 18 (1998) 255-262
31. Suzuki S., Toyabe S., Moroda T., Tada T., Tsukahara A., Iiai T., Minagawa M., Maruyama S., Hatakeyama K., Endoh K., and Abo T. Circadian rhythm of leucocytes and lymphocytes subsets and its possible correlation with the function of the autonomic nervous system. Clin. Exp. Immunol. 110 (1997) 500-508
32. Tompkins W.A. Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action. J. Interferon Cytokine Res. 19 (1999) 817-828
33. Tupasi T.E., Co V.M., Clarin M.S., Alesna E.T., Divinagracia E.M., and Mangubat N.V. Randomized, double-blind, placebo-controlled trial of oromucosal low-dose interferon following prednisone withdrawal for chronic hepatitis B infection in Filipino patients. Int. J. Infect Dis. 6 (2002) 37-41
34. Uno K., Sato T., Takada Y., Fujioka K., Suginoshita Y., Kakimi K., Moriyasu F., and Kishida T. A bioassay for serum interferon based on induction of 2′,5′-oligoadenylate synthetase activity. J. Interferon Cytokine Res. 18 (1998) 1011-1018
35. von Herrath M.G., and Oldstone M.B. Interferon-gamma is essential for destruction of beta cells and development of insulin-dependent diabetes mellitus. J. Exp. Med. 185 (1997) 531-539
36. Young A.S., Maritim A.C., Kariuki D.P., Stagg D.A., Wafula J.M., Mutugi J.J., Cummins J.M., Richards A.B., and Burns C. Low-dose oral administration of human interferon alpha can control the development of Theileria parva infection in cattle. Parasitology 101 Pt 2 (1990) 201-209